Physician profile
Minisha Sood
NPI 1144420043
$90,681.19
in general payments reported to CMS, 2019-2025
54 companies · $2,332 in 2025
The $2,332 reported for 2025 was more than what 79% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $36K · 2020: $22K · 2021: $19K · 2022: $3,867 · 2023: $6,484 · 2024: $2,225 · 2025: $2,332.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,097 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $3,600 · Travel and Lodging: $195 · Education: $89.54 · Gift: $59.40.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,096.89 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $3,600.00 |
| Travel and Lodging | $195.30 |
| Education | $89.54 |
| Gift | $59.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $55,997.58 | 2019-2025 | |
| Mannkind Corporation | $15,208.15 | 2019-2025 | Afrezza |
| Astrazeneca Pharmaceuticals LP | $7,480.56 | 2019-2025 | Farxiga |
| Novo Nordisk INC | $1,710.41 | 2019-2025 | Ozempic, Wegovy, Rybelsus |
| Lilly USA, LLC | $1,472.42 | 2019-2025 | Jardiance, Mounjaro, Zepbound |
| Abbvie INC. | $1,439.13 | 2019-2025 | Synthroid, Ubrelvy, Linzess |
| Amgen INC. | $1,021.90 | 2019-2025 | Evenity, Prolia, Tepezza |
| Pfizer INC. | $691.83 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $554.55 | 2019-2021 | |
| Astellas Pharma US INC | $496.83 | 2023-2025 | Veozah |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $365.85 | 2019-2024 | Xifaxan, Trulance |
| Ibsa Pharma INC. | $337.72 | 2019-2023 | Tirosint, Licart |
| Antares Pharma, INC. | $332.41 | 2020-2025 | Xyosted, Nocdurna, Tlando |
| Currax Pharmaceuticals LLC | $325.71 | 2019-2025 | Contrave, Nexletol, Nexlizet |
| Bayer Healthcare Pharmaceuticals INC. | $311.25 | 2021-2025 |
Show all 54 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amneal Pharmaceuticals LLC | $265.93 | 2021-2023 | Unithroid |
| Radius Health, INC. | $228.87 | 2019-2025 | Tymlos, Binosto |
| Xeris Pharmaceuticals, INC. | $191.49 | 2021-2024 | Recorlev, Gvoke Hypopen |
| Tandem Diabetes Care, INC. | $139.03 | 2020-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Dexcom, INC. | $123.76 | 2021-2024 | Dexcom G6 Transmitter |
| Aytu Biopharma, INC. | $122.69 | 2019-2020 | |
| Corcept Therapeutics | $120.20 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $111.09 | 2019-2021 | |
| Ipsen Biopharmaceuticals, INC | $110.40 | 2019-2022 | |
| Medtronic, INC. | $107.27 | 2021-2025 | Minimed 780g |
| Horizon Therapeutics Plc | $104.45 | 2022-2023 | Tepezza |
| Chiesi USA, INC. | $92.78 | 2024-2025 | Mycapssa |
| Shire North American Group INC | $90.19 | 2019 | |
| Esperion Therapeutics, INC. | $86.57 | 2021-2024 | Nexletol |
| Acella Pharmaceuticals, LLC | $78.67 | 2023-2025 | NP Thyroid 60 |
| Intra-Sana Laboratories | $77.65 | 2023 | Reltone 200 Mg, Glycate, Reltone 400 Mg |
| Ascendis Pharma Endocrinology INC | $74.02 | 2025 | Yorvipath |
| Insulet Corporation | $72.76 | 2019-2025 | Omnipod |
| Ascensia Diabetes Care US INC. | $64.43 | 2021-2025 | |
| Abbott Laboratories | $63.02 | 2019-2021 | |
| Madrigal Pharmaceuticals | $63.01 | 2025 | Rezdiffra |
| Alexion Pharmaceuticals, INC. | $57.78 | 2019-2022 | |
| Cequr Corporation | $53.44 | 2022 | |
| Tolmar, INC. | $49.41 | 2024 | |
| Janssen Pharmaceuticals, INC | $47.73 | 2019-2020 | |
| Recordati_rare_diseases_inc. | $43.99 | 2023 | Isturisa, Signifor Lar |
| Halozyme INC | $42.39 | 2023 | |
| Clarus Therapeutics INC. | $37.30 | 2021 | |
| Becton, Dickinson and Company | $36.97 | 2019-2021 | |
| Nalpropion Pharmaceuticals LLC | $30.71 | 2019 | |
| Grt US Holding, INC. | $22.70 | 2022 | |
| Eisai INC. | $20.50 | 2019 | |
| Valeritas, INC. | $20.33 | 2019 | |
| Kyowa Kirin, INC. | $16.22 | 2023 | |
| Zealand Pharma US, INC. | $16.21 | 2021 | |
| Acerus Pharmaceuticals Corporation | $14.97 | 2021 | |
| Amryt Pharma Holdings LTD | $14.39 | 2023 | Mycapssa |
| Vistapharm, INC. | $13.55 | 2021 | |
| Vivus LLC | $8.02 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Minisha Sood listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.